Literature DB >> 2996344

Converting enzyme inhibitor therapy limits progressive glomerular injury in rats with renal insufficiency.

T W Meyer, S Anderson, H G Rennke, B M Brenner.   

Abstract

Sustained increases in glomerular capillary pressure and flow accompany systemic hypertension in rats that have undergone extensive ablation of the renal mass. These intrarenal hemodynamic changes are, in turn, associated with the progressive development of proteinuria and glomerular sclerosis, leading ultimately to failure of remnant nephron units. The efficacy of antihypertensive therapy with enalapril was evaluated in this animal model of chronic renal insufficiency. A dose of enalapril sufficient to prevent systemic hypertension normalized the glomerular capillary pressure without reducing the glomerular filtration rate in the remnant kidney. Maintenance of normal capillary pressure markedly reduced the development of proteinuria and sclerotic lesions in remnant glomeruli. These results suggest that antihypertensive therapy directed at reducing the glomerular capillary pressure could retard the progressive loss of renal function in patients whose functional renal mass has been reduced by disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996344     DOI: 10.1016/0002-9343(85)90077-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  12 in total

1.  Failure of angiotensin converting enzyme inhibition to affect the course of chronic puromycin aminonucleoside nephropathy.

Authors:  G N Marinides; G C Groggel; A H Cohen; T Cook; R L Baranowski; C Westenfelder; W A Border
Journal:  Am J Pathol       Date:  1987-11       Impact factor: 4.307

Review 2.  Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure.

Authors:  J A Balfour; K L Goa
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.

Authors:  A A Taylor; S Sunthornyothin
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 4.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 5.  Renal effects of antihypertensive drugs.

Authors:  W A Schlueter; D C Batlle
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 6.  Angiotensin converting enzyme (ACE) inhibitors and renal function. A review of the current status.

Authors:  A L Kamper
Journal:  Drug Saf       Date:  1991 Sep-Oct       Impact factor: 5.606

Review 7.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

Review 8.  Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?

Authors:  M P Sambhi; H Gavras; J I Robertson; W M Smith
Journal:  West J Med       Date:  1993-03

9.  Glomerular epithelial cell function and pathology following extreme ablation of renal mass.

Authors:  M M Schwartz; A K Bidani; E J Lewis
Journal:  Am J Pathol       Date:  1987-02       Impact factor: 4.307

10.  Hyperglycemia and renal mass ablation synergistically augment albuminuria in the diabetic subtotally nephrectomized rat: implications for modeling diabetic nephropathy.

Authors:  Li-Hao Chen; Bailey Stead; Suzanne L Advani; Noreen Yaqoob; Kerri Thai; M Golam Kabir; Darren A Yuen; Kim A Connelly; Richard E Gilbert; Andrew Advani
Journal:  Nephron Extra       Date:  2012-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.